Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled the biotech's stock to a staggering 714% surge since the completion of the drug's Phase 1 trial on March 28, 2023.

Image Source: Getty Images.

Two key factors have fueled investor enthusiasm:

Continue reading

Source Fool.com